Ariad Pharmaceuticals, Inc. Announces Initiation of Phase 2 Trial of Ponatinib in Patients With Gastrointestinal Stromal Tumors
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the Phase 2 trial of Iclusig® (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy.
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the Phase 2 trial of Iclusig® (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy.
Help employers find you! Check out all the jobs and post your resume.